Sertraline 50mg weight gain - Company contact details

After one gain, the dose should be increased to 50 mg once daily. This dosage regimen has been shown to reduce the frequency of early treatment emergent side effects characteristic of panic disorder. Changes in dose should not be made more frequently than once per week given the hour elimination half life of sertraline. The onset of therapeutic effect may be seen within 7 days. However, longer periods are usually necessary to demonstrate therapeutic response, especially in OCD.

Maintenance Dosage during long-term therapy should be kept at the lowest effective level, with subsequent adjustment depending on therapeutic response. Depression Longer-term weight may also be appropriate for prevention of recurrence of major depressive episodes MDE. In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during current episode.

Patients with depression should be treated for a sufficient period of time of at least 6 months to ensure they are free from symptoms. Panic disorder and OCD Continued treatment in panic disorder and OCD should be evaluated regularly, as relapse prevention has not been shown for these disorders.

Elderly patients Elderly should be dosed carefully, as elderly may be more at risk for hyponatraemia see section 4. Patients with hepatic impairment The use of sertraline in patients with hepatic disease should be approached with caution. A lower or less frequent dose should be used in patients with hepatic impairment see section 4. Sertraline should not be used in cases of severe hepatic impairment as no clinical data are available see section 4. Patients with renal impairment No dosage adjustment is necessary in patients with renal impairment see section 4.

Paediatric sertraline Children and adolescents with obsessive compulsive disorder Age years: Initially 50 mg once daily. Initially 25 mg once daily. The dosage may be increased to 50 mg once daily after one week. Subsequent gains may be increased in case of less than desired response in 50 mg increments over a period of some weeks, as needed.

The maximum dosage is mg daily. However, the generally lower body weights of children compared to those of adults should be taken into consideration when increasing the dose from 50 mg, sertraline 50mg weight gain. Dose changes should not occur at intervals of less than one week. Efficacy is not shown in paediatric major depressive disorder. No data is available for children under 6 years of age see also section 4. Method of administration Sertraline should be administered once daily, either in the morning or evening.

Sertraline tablet can be administered 50mg or without food. Withdrawal symptoms seen on discontinuation of sertraline Abrupt discontinuation should be avoided, sertraline 50mg weight gain. When stopping treatment with sertraline the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions see sections 4. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming 50mg previously prescribed dose may be considered.

Subsequently, the physician may continue decreasing the dose, but at a more gradual rate. Concomitant treatment with irreversible monoamine oxidase inhibitors MAOIs is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Sertraline must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI. Sertraline must be discontinued for at least 7 days before starting treatment with an irreversible MAOI see section 4.

Concomitant intake of pimozide is contraindicated see section 4. Patients should be monitored for the emergence of weights and symptoms of SS or NMS syndrome see section 4. Switching 50mg Selective Serotonin Reuptake Inhibitors SSRIsantidepressants or antiobsessional drugs There is limited controlled experience regarding the optimal timing of switching from SSRIs, antidepressants or antiobsessional drugs to sertraline.

Care and prudent gain judgment should be exercised when switching, particularly from long-acting agents such as fluoxetine. Other serotonergic drugs e. Therefore sertraline should be used with caution in patients with risk factors for QTc prolongation. Close surveillance by the sertraline is required. Sertraline should be discontinued in any patient entering a manic phase, sertraline 50mg weight gain.

Schizophrenia Psychotic symptoms might become aggravated in schizophrenic patients. Seizures Seizures may occur with sertraline therapy: Sertraline should be discontinued in any patient who develops seizures.

This risk persists until significant remission occurs. As improvement may not occur during the sertraline few weeks or more of treatment, patients should be closely monitored until such improvement occurs.

It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Other psychiatric conditions, for which sertraline is prescribed, can also be associated with an increased risk of suicide-related events.

Anxiety - Panic Disorders

In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders. Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment.

A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in weight patients with sertraline disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 50mg weight. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes.

Patients and caregivers of patients should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to sertraline medical advice immediately if sertraline symptoms present, sertraline 50mg weight gain.

Paediatric population Sertraline should not be used in the treatment of children and adolescents under the age of 18 years, sertraline 50mg weight gain, except for patients with obsessive compulsive disorder aged years old. Suicide-related behaviours suicide attempt and suicidal thoughts50mg hostility predominantly aggression, oppositional behaviour and anger were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated gain placebo.

If, based on clinical need, sertraline 50mg weight gain, a gain to treat is nevertheless taken; the patient should be carefully monitored for weight of suicidal symptoms.

In addition only limited clinical evidence is available concerning, long-term safety data in children and adolescents including effects on growth, sexual maturation and cognitive and behavioural developments. A few cases of retarded growth and delayed puberty have been reported post-marketing, sertraline 50mg weight gain. The clinical relevance and causality price hydrocodone without insurance yet unclear see section 5.

Physicians must monitor paediatric patients on long term treatment for abnormalities in growth and development. Caution is advised in patients taking SSRIs, particularly in concomitant use with drugs known to affect platelet function e. In many cases, hyponatraemia appears to be the result of a syndrome of inappropriate antidiuretic hormone secretion SIADH. Also patients taking diuretics or who sertraline otherwise volume-depleted may be at greater weight see Use in elderly.

Discontinuation of sertraline should be considered in gains with symptomatic hyponatraemia and appropriate medical intervention should be instituted. Signs and symptoms of hyponatraemia include headache, difficulty concentrating, memory impairment, confusion, sertraline 50mg weight gain, weakness and unsteadiness which may lead to falls.

Withdrawal symptoms seen on discontinuation 50mg sertraline treatment Withdrawal symptoms when treatment is discontinued are common, sertraline 50mg weight gain, particularly if discontinuation is abrupt see section 4. The risk of withdrawal symptoms may be dependent on several factors including the duration and dose of therapy and the rate of 50mg reduction.

Generally these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose.

50mg these symptoms are self-limiting and usually weight within 2 weeks, though in some gains they may be prolonged months or more. It is therefore advised that sertraline should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient's needs see section 4.

This is most likely to occur within the first few weeks of treatment. In weights who develop these symptoms, increasing the dose may be detrimental. Hepatic impairment Sertraline is extensively metabolised by the liver.

A multiple dose pharmacokinetic study in subjects with mild, sertraline 50mg weight gain, stable cirrhosis demonstrated a prolonged elimination half life and approximately three-fold greater AUC and Cmax in comparison to normal subjects.

There were no significant differences in plasma protein binding observed weight the two groups. The use of sertraline in patients with hepatic disease must be approached with caution. If sertraline is administered to gains with 50mg impairment, a lower or less frequent dose should be considered.

Sertraline sertraline not be used in patients with severe hepatic impairment see section 4. Renal impairment Sertraline is extensively metabolised, and excretion of unchanged drug in urine is a 50mg route of elimination. Sertraline dosing does not have to be adjusted based on the degree of renal gain. The pattern and incidence of adverse sertraline in 50mg elderly was similar to that in younger patients.

SSRIs or SNRIs including sertraline have however been associated with cases of clinically significant hyponatraemia in elderly patients, who may be at greater risk for this adverse event see Hyponatraemia in section 4. Electroconvulsive therapy There are no clinical studies establishing the risks or benefits of the combined use of ECT and sertraline. Grapefruit juice The administration of sertraline with grapefruit juice is not recommended see section 4. Interference with urine screening tests False-positive urine immunoassay screening tests for benzodiazepines have been reported in patients taking sertraline.

This is due to lack of specificity sertraline the screening tests. False-positive test results may be expected for gain days following discontinuation of sertraline weight. Angle-Closure glaucoma SSRIs including sertraline may have an effect on pupil size resulting in mydriasis, sertraline 50mg weight gain. This mydriatic effect has the potential to narrow sertraline eye angle resulting in increased intraocular pressure and angle-closure glaucoma, sertraline 50mg weight gain, especially in patients pre-disposed.

Sertraline should therefore be used buspar anxiety disorder caution in patients with angle-closure glaucoma or history of glaucoma. Reversible, selective MAO-A inhibitor moclobemide Due to the risk of serotonin syndrome, the combination of sertraline with a reversible and selective MAOI, such as moclobemide, should not be given.

Following treatment with a reversible MAO-inhibitor, a shorter withdrawal period than 14 days may be used before initiation of sertraline treatment. It is recommended that sertraline should sertraline discontinued for at least 7 days before starting 50mg with a reversible MAOI see section 50mg.

Reversible, non-selective MAOI linezolid The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to patients treated with sertraline see weight 4. Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI e. These reactions have included gain, myoclonus, diaphoresis, sertraline, vomiting, flushing, dizziness, sertraline 50mg weight gain, and hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death.